Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (81-90 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerNancy U Lin, Lisa A Carey, Minetta C Liu, et al.
Breast Cancer Research and Treatment|September 16, 2017
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancerRoberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast CancerJodi M Carter, Mei-Yin C Polley, Roberto A Leon-Ferre, et al.
Oncogene|March 6, 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistanceMohammad Jalalirad, Tufia C Haddad, Jeffrey L Salisbury, et al.
Scientific Reports|November 28, 2024
Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapyChiara Molinari, Giorgia Marisi, George Laliotis, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
NPJ Breast Cancer|June 12, 2021
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patientsCostanza Paoletti, Meredith M Regan, Samuel M Niman, et al.
BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.
Pageof 16

Showing results (81-90 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerNancy U Lin, Lisa A Carey, Minetta C Liu, et al.
Breast Cancer Research and Treatment|September 16, 2017
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancerRoberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast CancerJodi M Carter, Mei-Yin C Polley, Roberto A Leon-Ferre, et al.
Oncogene|March 6, 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistanceMohammad Jalalirad, Tufia C Haddad, Jeffrey L Salisbury, et al.
Scientific Reports|November 28, 2024
Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapyChiara Molinari, Giorgia Marisi, George Laliotis, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
NPJ Breast Cancer|June 12, 2021
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patientsCostanza Paoletti, Meredith M Regan, Samuel M Niman, et al.
BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.
Pageof 16